Endometriosis is a chronic gynecological condition affecting millions of women worldwide, characterized by the growth of endometrial-like tissue outside the uterus. This condition often leads to debilitating pelvic pain, irregular menstrual cycles, and in some cases, infertility. Managing endometriosis pain effectively has long been a challenge for healthcare providers. In response to this need, Steris Healthcare Pvt. Ltd. has introduced ELIGOLUX 150 mg and 200 mg, a groundbreaking treatment designed to provide targeted relief from endometriosis-associated pain.
Introduction
ELIGOLUX, available in 150 mg and 200 mg tablets, is a pharmaceutical innovation developed by Steris Healthcare that contains Elagolix, a non-peptide, oral gonadotropin-releasing hormone (GnRH) antagonist. This medication works by modulating hormone levels, specifically reducing the production of estrogen, which is a key factor in the growth and maintenance of endometriotic lesions. By targeting estrogen production, ELIGOLUX helps alleviate pain and improve the overall quality of life for women suffering from this chronic condition.
What makes ELIGOLUX unique is its oral administration and precise dosing options—150 mg for moderate symptoms and 200 mg for severe endometriosis pain—providing flexibility and effective symptom management tailored to individual patient needs. Steris Healthcare’s introduction of this therapy marks a significant advancement in women’s health, offering an evidence-based alternative to traditional hormonal therapies and surgical interventions.
Uses of ELIGOLUX 150 mg & 200 mg
ELIGOLUX is specifically indicated for the treatment of moderate to severe pain associated with endometriosis. This includes:
Dysmenorrhea: Painful menstrual cramps caused by endometriotic lesions.
Non-menstrual pelvic pain: Chronic pelvic discomfort not directly related to menstruation.
Dyspareunia: Pain during sexual intercourse associated with endometriosis.
By targeting the hormonal pathways that fuel endometriotic growth, ELIGOLUX helps reduce inflammation and lesion activity, effectively alleviating both acute and chronic symptoms of endometriosis.
Steris Healthcare’s therapy is suitable for women seeking long-term symptom control without the need for invasive procedures, providing a non-surgical option for managing a condition that often significantly impacts daily life and mental well-being.
Mechanism of Action
Elagolix, the active ingredient in ELIGOLUX, works as a GnRH receptor antagonist. Normally, the hypothalamus releases GnRH to stimulate the pituitary gland, which in turn triggers the production of estrogen and progesterone in the ovaries. In endometriosis, higher levels of estrogen contribute to the growth and maintenance of endometrial lesions.
ELAGOLIX directly inhibits GnRH receptors, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, which subsequently decreases ovarian estrogen production. This reduction in estrogen leads to:
Shrinkage of endometriotic lesions
Reduced inflammation in affected tissues
Relief from pain and pelvic discomfort
The oral administration of ELAGOLIX allows rapid onset of action and dose-dependent hormone suppression, enabling physicians to tailor therapy based on symptom severity.
Benefits of ELIGOLUX 150 mg & 200 mg
ELIGOLUX provides multiple benefits to women managing endometriosis pain:
Effective Pain Relief: Clinical studies show significant reduction in dysmenorrhea, non-menstrual pelvic pain, and dyspareunia.
Non-Surgical Option: Offers a non-invasive alternative for women who prefer to avoid surgery.
Flexible Dosing: 150 mg for moderate pain and 200 mg for severe pain, allowing personalized treatment.
Improved Quality of Life: Reduces daily discomfort and enhances physical and emotional well-being.
Rapid Onset: Pain relief is observed within weeks of starting treatment.
Evidence-Based: Supported by multiple clinical trials demonstrating efficacy and safety in long-term use.
By effectively managing endometriosis symptoms, ELIGOLUX enables women to maintain daily routines, work productivity, and social interactions without being limited by pain.
Dosage and Administration
ELIGOLUX should always be used under the supervision of a qualified healthcare professional. Standard dosing recommendations include:
ELIGOLUX 150 mg: Taken once daily for women with moderate endometriosis-related pain.
ELIGOLUX 200 mg: Taken once daily for severe endometriosis pain requiring more intensive hormone suppression.
Administration tips:
Take the tablet orally with water
Can be taken with or without food
Do not crush or chew the tablet
Regular monitoring of hormone levels may be recommended for long-term therapy
Treatment duration is typically individualized based on symptom severity and response, with periodic assessment by the prescribing physician to optimize outcomes.
Side Effects
Like all medications, ELIGOLUX may cause some side effects. Common adverse effects include:
Hot flashes or flushing
Headache
Nausea
Fatigue
Reduced bone mineral density with prolonged use
Less common but serious effects may include significant bone loss or changes in liver function, which require careful monitoring. It is important to discuss any pre-existing medical conditions with your doctor before starting ELIGOLUX.
Precautions and Warnings
Before starting ELIGOLUX, patients should consider the following precautions:
Not recommended during pregnancy or breastfeeding
Monitor bone density if used for long-term treatment
Avoid combining with other hormonal therapies unless advised by a physician
Inform your doctor about liver disease, osteoporosis, or any history of cardiovascular conditions
Regular check-ups and lab tests are recommended to ensure safe and effective therapy.
Conclusion
Steris Healthcare Pvt. Ltd. has set a new benchmark in endometriosis care with ELIGOLUX 150 mg and 200 mg tablets, offering women an effective, non-surgical solution for managing moderate to severe endometriosis pain. With its novel mechanism, flexible dosing, and proven efficacy, ELIGOLUX empowers women to regain control over their lives, significantly improving physical comfort and emotional well-being.
By providing an oral, patient-friendly alternative, Steris Healthcare continues its commitment to innovative solutions in women’s health, ensuring that those affected by endometriosis have access to safe, effective, and convenient treatment options.
